0000899243-17-022210.txt : 20170918 0000899243-17-022210.hdr.sgml : 20170918 20170918163536 ACCESSION NUMBER: 0000899243-17-022210 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170915 FILED AS OF DATE: 20170918 DATE AS OF CHANGE: 20170918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: IVERS-READ GILLIAN C CENTRAL INDEX KEY: 0001268304 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 171090204 MAIL ADDRESS: STREET 1: C/O PHARMION CORPORATION STREET 2: 2525 28TH STREET CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-15 0 0001466301 Clovis Oncology, Inc. CLVS 0001268304 IVERS-READ GILLIAN C C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2017-09-15 4 S 0 3000 69.50 D 191583 D This transaction was executed in multiple trades at prices ranging from $69.30 to $69.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 6, 2017. Executive Vice President of Technical Operations and Chief Regulatory Officer /s/ Gillian C. Ivers-Read 2017-09-18